Objective: There is a need for inexpensive noninvasive tests to identify older healthy persons at risk for Alzheimer disease (AD) for enrollment in AD prevention trials. Our objective was to examine whether abnormalities in neuroimaging measures of amyloid and neurodegeneration are correlated with odor identification (OI) in the populationbased Mayo Clinic Study of Aging. Methods: Cognitively normal (CN) participants had olfactory function assessed using the Brief Smell Identification Test (B-SIT), underwent magnetic resonance imaging (n 5 829) to assess a composite AD signature cortical thickness and hippocampal volume (HVa), and underwent 11 C-Pittsburgh compound B (n 5 306) and 18 fluorodeoxyglucose (n 5 305) positron emission tomography scanning to assess amyloid accumulation and brain hypometabolism, respectively. The association of neuroimaging biomarkers with OI was examined using multinomial logistic regression and simple linear regression models adjusted for potential confounders. Results: Among 829 CN participants (mean age 5 79.2 years; 51.5% men), 248 (29.9%) were normosmic and 78 (9.4%) had anosmia (B-SIT score < 6). Abnormal AD signature cortical thickness and reduced HVa were associated with decreased OI as a continuous measure (slope 5 20.43, 95% confidence interval [CI] 5 20.76 to 20.09, p 5 0.01 and slope 5 20.72, 95% CI 5 21.15 to 20.28, p < 0.01, respectively). Reduced HVa, decreased AD signature cortical thickness, and increased amyloid accumulation were significantly associated with increased odds of anosmia. Interpretation: Our findings suggest that OI may be a noninvasive, inexpensive marker for risk stratification, for identifying participants at the preclinical stage of AD who may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials. These cross-sectional findings remain to be validated prospectively.
system (eg, olfactory epithelium, olfactory bulb, central olfactory cortex, or olfactory circuitry). 1 Olfactory impairment has been associated with cognitive decline, 5 mild cognitive impairment (MCI), 6 Alzheimer disease (AD) dementia, 7-11 vascular dementia, 12 Parkinson disease (PD), 13 dementia with Lewy bodies, 14 and the progression from MCI to AD dementia. 6, 8 In cognitively normal (CN) elderly individuals, worse odor identification (OI) has also been associated with markers of brain pathology, such as increased cortical amyloid and thinner entorhinal cortex, 15 and with neurofibrillary pathology in the entorhinal cortex and hippocampus in autopsy studies. 16 Thus, changes in olfactory function in CN persons could represent preclinical neurodegenerative disease. 3 There is a need for inexpensive noninvasive tests to identify older healthy persons potentially at risk for AD for enrollment in AD prevention trials. One of the earliest brain regions affected by AD is the olfactory system, 17, 18 suggesting that olfactory impairment may be an early sign of AD brain pathology, an intermediate marker in the causal pathway from brain biomarker pathology to cognitive impairment. Amyloid-b (Ab) accumulation has been described in areas of the olfactory network in AD and amnestic MCI participants but also in elderly persons with normal neuropsychological test scores. 19 A recent meta-analysis suggested that odor identification and recognition could be the most interesting candidate for inclusion in a group of biomarkers to detect subclinical AD, 20 especially when combined with clinical/neuropsychological 21 assessment and imaging biomarkers. 22 We hypothesized that in vivo neuroimaging biomarkers of AD pathology are associated with olfactory impairment among older CN individuals. The objective of the present study, therefore, was to examine the crosssectional associations between neuroimaging measures of amyloid accumulation and neurodegeneration and a simple measure of OI in a large population-based cohort of CN older persons.
Subjects and Methods

Study Population
Details of the Mayo Clinic Study of Aging (MCSA) design and methodology have been previously reported. 23, 24 Residents in Olmsted County, Minnesota aged 70 to 89 years on October 1, 2004 (prevalence index date) were enumerated using Rochester Epidemiology Project 25 resources, and an age-and sex-stratified random sample of eligible subjects (without dementia, not terminally ill or in hospice) was invited to participate. Ongoing recruitment was performed beginning from 2008 through 2011, using the same protocols as in 2004. Participants were comprehensively evaluated for a diagnosis of MCI 16 or dementia 26 and normal cognition as previously described. 23, 24 Overall, this analysis includes 829 CN participants (822 participants were white), who were recruited between 2004 and 2010, completed an in-person evaluation and the Brief Smell Identification Test (B-SIT), 27 and underwent magnetic resonance imaging (MRI). Of these individuals, 306 had 
Standard Protocol Approvals, Registrations, and Patient Consent
The study was approved by the institutional review boards of the Mayo Clinic and the Olmsted Medical Center. Written informed consent was obtained prior to participation in the study.
Assessment of Olfactory Function
Olfactory impairment was assessed using the B-SIT 27 version A, which consists of 6 food-related and 6 non-food-related smells (cherry, clove, strawberry, menthol, pineapple, lemon, leather, lilac, smoke, soap, natural gas, and rose). Participants had to scratch, sniff, and select 1 of 4 possible choices. The B-SIT score was calculated as the sum of the correct responses for persons with 2 missing responses; for persons with 1 (n 5 10) or 2 (n 5 4) missing responses, a score of 0.25 was assigned for each missing response. 7, 10 Olfactory impairment categories were defined by B-SIT score as anosmia (score < 6), hyposmia (or microsmia; men, 6-10; women, 6-10.25), and normosmia (men, 10.25-12; women, 10.5-12). 9 
Acquisition of MRI Measures
MRI studies were performed at 3T (Signa; GE Healthcare, Waukesha, WI) with an 8-channel phased-array head coil acquiring both a 3-dimensional magnetization-prepared rapidacquisition gradient echo sequence and a fluid-attenuated inversion recovery sequence. 28 Hippocampal volume (HVa) was measured using the FreeSurfer software (v5.3) and adjusted for total intracranial volume (n 5 821). 29 Cortical thickness was measured using FreeSurfer (v5.3), and an AD signature cortical thickness measure 30 was computed by averaging the cortical thickness for entorhinal, inferior temporal, middle temporal, and fusiform cortices (n 5 826).
18 F-FDG PET and 11 C-PiB PET Acquisition PET images were acquired using a PET/computed tomographic scanner operating in 3-dimensional mode. 31 A detailed 18 F-FDG PET and 11 C-PiB PET acquisition process has been published. [31] [32] [33] An amyloid PET standardized uptake value ratio (SUVR) was formed from the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, and posterior cingulate/precuneus regions of interest (ROIs) normalized to the whole cerebellum (n 5 306). 31 An AD signature 34 18 F-FDG PET SUVR
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(nonsharpened, non-partial volume corrected) was calculated based on glucose metabolic rates from an AD signature meta-ROI and consisted of the average bilateral angular gyri, posterior cingulate, and inferior temporal cortical ROIs from both hemispheres normalized to pons and vermis uptake (n 5 305).
35-37
Neuroimaging Biomarkers Cutpoints
The cutpoints for biomarker abnormality were defined such that 90% of a group of 75 clinically diagnosed AD dementia subjects from the Mayo Clinic Alzheimer Disease Research Center and MCSA were categorized as abnormal. Abnormal HVa was defined as <22.40cm 3 (adjusted for total intracranial volume); abnormal FDG PET was defined as SUVR < 1.32; abnormal AD signature cortical thickness was defined as < 2.74mm; abnormal amyloid PET was defined as SUVR > 1.40, and was validated by autopsy correlation with Thal amyloid phase. 30, 34, 38, 39 Covariates Information on age, sex, years of educational, body mass index (weight in kilograms divided by height in meters squared), smoking habits, self-reported alcohol problems, and gait speed (meters per second), was collected at the baseline evaluation; history of type 2 diabetes, hypertension, and stroke was obtained from medical record abstraction; apolipoprotein E (APOE) genotyping was performed at baseline.
Statistical Analysis
Cross-sectional associations of abnormal 11 C-PiB PET, abnormal AD signature 18 F-FDG PET (hypometabolism), abnormal AD signature cortical thickness, and abnormal HVa with the olfactory impairment categories were examined using multinomial logistic regression models (odds ratios [ORs], 95% confidence intervals [CIs]) having normosmia as the comparison group. Examination of the residuals of regressions of the continuous B-SIT score on abnormal neuroimaging biomarkers, adjusting for age, sex, and education, suggested linear associations. We also used multivariable linear regression models to examine the association (slope, 95% CIs) of abnormal biomarkers with continuous B-SIT as the dependent (outcome) variable. Separate models were fit with each neuroimaging biomarker as the independent (exposure) variable and the B-SIT score (categorical and continuous) as the dependent (outcome) variable. All models were adjusted for age (at B-SIT), sex, and education (basic model); total intracranial volume was included in models with amygdala volume. We assessed the interaction between abnormal Multinomial logistic regression models were also fit to additionally adjust (in separate models) for APOE 4 carrier status (4 carrier vs noncarrier), Unified Parkinson Disease Rating Scale, 40 the Boston Naming Test, 41 and history of head trauma (ie, the participants were asked "Have you ever experienced any head injuries that led you to see a doctor, stay in the hospital, lose your memory, or become unconscious"). A final model simultaneously adjusted for APOE e4 allele, type 2 diabetes, hypertension, stroke, self-reported alcohol problem, and ever smoking; the estimates were essentially unchanged; therefore, only estimates from the previous more parsimonious models are reported.
In multivariable linear regression models, the associations (slopes [beta estimates], 95% CIs) of MRI and PET ROI measurements in areas of the primary olfactory cortex (eg, amygdala, entorhinal cortex), the secondary olfactory regions (eg, hippocampus, hypothalamus, thalamus, insula, orbitofrontal cortex), and areas where odorant-induced activation has been recorded in previous functional MRI and PET studies (including precentral gyrus, superior and inferior temporal gyrus, cingulate gyrus, occipital lobe, parietal lobe, 42, 43 and inferior frontal gyrus 44 ) with continuous B-SIT score were examined. No mathematical correction 45 was applied for multiple comparisons to avoid increasing type II error, as the investigation broadly examined the associations of neuroimaging measures of amyloid and neurodegeneration and OI so as to generate hypotheses for future prospective studies. Associations were considered significant at p < 0.05, and were performed using SAS statistical software version 9.3 (SAS Institute, Cary, NC) and Stata/SE statistical software version 14.2 (StataCorp, College Station, TX). Table 1 presents characteristics of 829 participants by olfactory impairment categories. Of the 829 participants (mean age 5 79.2 years; 51.5% men), 248 (29.9%) were normosmic, 78 (9.4%) had anosmia, and 503 (60.7%) had hyposmia; anosmia was significantly more frequent in men. Thirty percent (n 5 249) of the participants had abnormal cortical thickness, and 15.5 % (n 5 128) had abnormal HVa. Among participants with available PET scans, 38.9% had abnormal ANNALS of Neurology 1.21-4.94, respectively, adjusting for age, sex, and education; Table 2 ). These estimates remained relatively stable with adjustments for APOE 4 allele, Unified Parkinson Disease Rating Scale, 40 the Boston Naming Test, 41 and history of head trauma in separate models (see Table 2 ). Biomarkers were not significantly associated with hyposmia. In analyses examining the association of imaging biomarkers with B-SIT as a continuous outcome variable, abnormal AD signature cortical thickness and abnormal HVa were significantly associated with lower B-SIT score (slope 5 20.43, 95% CI 5 20.76 to 20.09, p 5 0.01; slope 5 20.72, 95% CI 5 21.15 to 20.28, p < 0.01, respectively), adjusting for age, sex, and education (Table 3) .
Results
Characteristics of Participants
There were statistically significant interactions between abnormal (Table   4) . Interestingly, the point estimates for associations in Abn 5 persons with abnormal B-SIT; All 5 participants with and without abnormal biomarkers in the specific analysis strata; B-SIT 5 Brief Smell Identification Test; CI 5 confidence interval; OR 5 odds ratio; SUVR 5 standardized uptake value ratio. 
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The present study examined associations of amyloid deposition, markers of neurodegeneration, and neurodegeneration conditioned on amyloid status with OI. In this sample of CN elders, increased amyloid deposition, abnormal AD signature cortical thickness, and abnormal HVa were significantly associated with anosmia. Abnormal AD signature cortical thickness and abnormal HVa were significantly associated with decreasing B-SIT score.
The association of the B-SIT score with HVa could be driven by abnormal 11 C-PiB PET.
The present study examined associations of OI with neurodegeneration conditioned on amyloid status. The association of biomarkers of neurodegeneration (ie, reduced HVa and hypometabolism) with B-SIT remained statistically significant and was stronger in individuals with abnormal PiB. In addition, the A These results are partly in agreement with a previous study 15 that reported that in PiB-positive clinically normal participants, a thinner entorhinal cortex was associated with worse olfactory function. However, previous studies are few and inconclusive. Antemortem OI (using B-SIT) was demonstrated 16 to be negatively associated with postmortem AD brain pathology (amyloid load and tangle density); however, authors reported that when both measures of AD pathology were in the same analysis model, the association with tangles persisted but the association with amyloid was 70% attenuated. 16 Similar conclusions were reached in studies conducted in mouse models. 17 In addition, elevated soluble Ab has been associated with detrimental effects on neural circuits and altered connectivity of olfactory neurons in mice (overexpressing human APPsw [Swedish mutation]) before the onset of plaques. 48 Investigators 17 have demonstrated a moderate inverse linear association between OI and PiB binding (global or regional) when pooling together individuals with AD, amnestic MCI and healthy elderly controls, but the association was not verified within each of these groups.
In the present study, abnormal 11 C-PiB PET scan was strongly associated with anosmia. Although we cannot assess a temporal relationship between amyloid deposition and OI impairment, this finding might suggest that a threshold of AD pathology burden in CN individuals might be necessary for severe OI to be present. We did not measure tau; thus, we cannot determine whether overall the burden of AD pathology (ie, both amyloid and tau deposits) was increased, but given the study population median age (78.4 years), we could speculate that nearly all participants had some level of neurofibrillary tangle pathology. 29, 49 Aging is characterized also by a decrease in cortical thickness 3 and hippocampal volume. We considered atrophy on MRI as a measure of neurodegeneration 29 ; however, hippocampal atrophy is not specific for AD. It could represent other age-related processes leading to neurodegeneration, including tauopathy. 29 Investigators 18 have found that worse OI was associated with smaller hippocampal volume in a group of MCI and AD patients but not in healthy individuals; however, the authors acknowledged the need for larger studies. 18 In additional previous reports, OI scores cross-sectionally correlated with hippocampal volume in a study of nondemented elders, 50 OI deterioration prospectively correlated with decreased hippocampal volume (and cognitive function deterioration) among MCI patients, 21 and it was associated with greater AD pathology (based on a composite measure including neuritic plaques, diffuse F-FDG PET SUVR that was calculated based on glucose metabolic rates from an AD signature meta-region of interest (ROI) and that consisted of the average bilateral angular gyri, posterior cingulate, and inferior temporal cortical ROIs from both hemispheres normalized to pons and vermis uptake.
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plaques, and neurofibrillary tangles) in an autopsy study of individuals without cognitive impairment. 51 The present study examined the association of abnormal (decreased) cortical thickness specifically in AD signature cortical regions with OI, 30 which we expect would most likely differentiate those individuals at risk for clinical AD. Having abnormal AD signature cortical thickness (vs not having abnormal AD signature cortical thickness) was most strongly associated with severe OI impairment (anosmia vs normosmia). We observed significant positive associations between AD signature cortical thickness (as a continuous measure), entorhinal, temporal pole, and parahippocampal cortical thicknesses, key regions associated with olfaction and with cortical atrophy in AD dementia, and B-SIT score. In patients with early AD, OI scores were associated with normalized FDG uptake with peaks in the right inferior frontal gyrus, right fusiform gyrus, precuneus, and superior parietal lobe. 44 In the present study, FDG ROIs of the olfactory pathway and AD pathology including amygdala, hippocampal, entorhinal, or olfactory ROIs showed significant positive associations with B-SIT score. However, abnormal AD 18 F-FDG PET ratio was associated with B-SIT only in those with abnormal 11 C-PiB PET. Potential explanations could include that the abnormal AD 18 F-FDG PET ratio does not include key areas of the olfactory pathway (ie, it includes average bilateral angular gyri, posterior cingulate, and inferior temporal) or that OI may precede brain hypometabolism in those areas early in the AD process, especially when the Ab burden is not significant (ie, in individuals without abnormal PiB PET).
AD pathology develops several decades 52 prior to AD symptomatology. Current cross-sectional findings if validated in prospective studies are clinically relevant, as the olfactory system demonstrates measurable impairment in the early preclinical stages of the disease when the AD pathological markers are also present. 17 Because of the nature of the logistic models, when analysis direction is reversed, the results are quite similar, suggesting that in a clinical setting OI could be used as a marker for neuroimaging abnormality. The association of imaging biomarker abnormalities with OI suggests that OI may be a noninvasive, inexpensive marker for risk stratification, for identifying participants at the preclinical stage of AD who may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials. Although olfactory assessment cannot currently be used as a standalone diagnostic test, 17 a combination of olfactory assessment with other AD biomarkers (eg, imaging biomarkers) could strengthen the AD diagnostic sensitivity and specificity. 17, 53 However, our findings are preliminary and remain to be validated prospectively.
Limitations of the study should be considered when interpreting the results. The cross-sectional study design precludes our ability to assess causality. Participants in imaging studies performed slightly better cognitively and had a slightly lower frequency of hypertension than individuals without imaging studies, suggesting a potential bias of our estimates toward the null. Analysis stratified by PiB status (normal/abnormal) suggested lower precision and could have overestimated the point estimates. Lastly, the population of Olmsted County, Minnesota that is 70 years or older is predominantly white of European ancestry; thus, assessment of these associations in more heterogeneous populations would be of interest.
Despite the potential limitations, the study has several important strengths. The population-based design diminishes potential selection bias. Cognitive status was comprehensively assessed using published criteria, without consideration of any previous diagnoses, thereby reducing the potential bias in ascertainment of CN status. In addition, reliable measures of brain pathology were ascertained by multimodal, state-of-the-art imaging and the study had a relatively large sample size.
